免疫疗法与骨放射治疗相结合,用于驱动性阴性非小细胞肺癌脑转移:一项回顾性研究
Shuangqing Lu1, Xiaokang Guo2, Zhengqiang Yang1
1Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong Province, 250117, China.
Future oncology (London, England)
|April 9, 2024
概括
结合脑辐射疗法 (CRT) 和免疫检查点抑制剂,显著改善了脑转移 (BM) 的非小细胞肺癌 (NSCLC) 患者的长期存活率. 这种方法提供了一个有前途的策略来管理与大脑参与的先进NSCLC.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 辐射瘤学 辐射瘤学
背景情况:
- 带有大脑转移 (BM) 的非小细胞肺癌 (NSCLC) 是一个重大的临床挑战.
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗,但它们在BM的有效性是积极研究的领域.
- 部放射治疗 (CRT) 与ICI等全身疗法的作用需要进一步阐明.
研究的目的:
- 评估免疫检查点抑制剂在患有BM的NSCLC患者的疗效.
- 探索结合CRT与ICI对患者生存结果的影响.
- 为了确定与这种患者群体中改善生存率相关的预后因素.
主要方法:
- 在2018年7月至2021年12月期间接受治疗的113名NSCLC患者的回顾性分析.
- 患者接受了与ICI结合的第一线化疗.
- 在使用CRT和不使用CRT的组之间比较总生存 (OS),无进展生存 (PFS) 和内PFS.
主要成果:
- 与没有CRT的患者相比,与ICI同时接受CRT的患者表现出显著改善的中位数OS (未达到vs15.31个月).
- CRT的益处在患有1到3个BM的患者中尤为明显.
- 与更好的生存状况相关的因素包括CRT,PD-L1表达和特定诊断的分级预后评估得分.
结论:
- 将CRT与抗PD-1疗法的整合显著提高了BM的NSCLC患者的长期存活率.
- 当与免疫疗法相结合时,CRT可能在改善有限脑转移的NSCLC患者的治疗结果方面发挥关键作用.
- 这种综合方法代表了一种有前途的策略,用于管理先进的NSCLC与内疾病.
更多相关视频
相关概念视频
Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


